Allogeneic Stem Cell Transplant Rejection

Comprehensive Clinical Guide: Allogeneic Stem Cell Transplant Rejection

1. Introduction and Clinical Overview

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) represents a curative therapeutic modality for a variety of malignant and non-malignant hematologic disorders, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and severe aplastic anemia. Despite its life-saving potential, the procedure is fundamentally defined by the immunological challenge of introducing non-self-antigens into a recipient.

"Rejection" in the context of allo-HSCT refers to the immunological failure of the graft to engraft or the subsequent destruction of the donor-derived hematopoietic cells by the recipient’s residual immune system. While often conflated with Graft-versus-Host Disease (GvHD), rejection is a distinct phenomenon characterized by graft failure. In rejection, the host immune system recognizes and attacks the donor cells, whereas in GvHD, the donor immune system recognizes and attacks the host tissues.

2. Deep-Dive: Mechanisms and Pathophysiology

The pathophysiology of transplant rejection is primarily driven by the persistence of host-derived T-lymphocytes or Natural Killer (NK) cells that survive the conditioning regimen.

The Immunological Cascade

1. Residual Host Immunity: Despite myeloablative conditioning, some host T-cells may remain. These cells express T-cell receptors (TCRs) that recognize donor Human Leukocyte Antigens (HLA) as foreign.
2. Allorecognition: The mismatch between donor and recipient HLA molecules triggers a massive cytokine release (IFN-γ, TNF-α, IL-2).
3. Effector Phase: Cytotoxic T-lymphocytes (CTLs) infiltrate the bone marrow niche, inducing apoptosis in donor-derived hematopoietic stem and progenitor cells (HSPCs).
4. NK Cell Involvement: In cases of HLA-mismatched transplants, "missing self" recognition by host NK cells can lead to rapid destruction of donor cells.

Factors Influencing Rejection Risk

3. Clinical Staging, Grading, and Presentation

Rejection is clinically categorized based on the temporal relationship to the transplant procedure.

• Primary Graft Failure: Absolute failure of the donor cells to achieve hematologic recovery (neutrophils < 0.5 x 10⁹/L) by day 28 post-transplant.
• Secondary Graft Failure: Initial engraftment followed by a subsequent, irreversible decline in blood counts (cytopenia) in at least two lineages.

Clinical Presentation

Patients often present with persistent pancytopenia. Symptoms include:
* Anemia: Fatigue, tachycardia, dyspnea.
* Thrombocytopenia: Petechiae, mucosal bleeding, ecchymosis.
* Neutropenia: Increased susceptibility to opportunistic bacterial and fungal infections.
* Fever: Often associated with underlying infection secondary to prolonged neutropenia.

4. Diagnostic Workup and Differential Diagnosis

Diagnosing graft rejection requires a systematic approach to rule out other causes of cytopenia.

Key Diagnostic Tests

1. Chimerism Analysis: The gold standard. Utilizing Short Tandem Repeat (STR) PCR, clinicians measure the percentage of donor vs. host cells in the bone marrow and peripheral blood. A precipitous drop in donor chimerism is diagnostic of rejection.
2. Bone Marrow Biopsy/Aspirate: Assesses cellularity and identifies potential marrow fibrosis or residual leukemic disease.
3. HLA Antibody Screening: Detection of Donor-Specific Antibodies (DSA) in the recipient’s serum.
4. Viral PCR Panels: Screening for CMV, EBV, and HHV-6, which can cause bone marrow suppression.

Differential Diagnosis Table

5. Management Strategies and Prognosis

Management is complex and depends on the underlying mechanism of rejection.

• Immunosuppressive Tapering: In some cases, reducing immunosuppression may allow the graft to recover, though this risks triggering GvHD.
• Donor Lymphocyte Infusion (DLI): Attempting to boost the graft, though rarely effective if the rejection is host-mediated.
• Second Transplant: The definitive rescue strategy. This requires re-conditioning and a new stem cell source, often with a different donor to avoid the original immunological barrier.

Long-Term Prognosis

The prognosis for patients with graft rejection is guarded. Mortality is significantly higher than in patients with successful engraftment, primarily due to infectious complications during the prolonged neutropenic window. Early identification via routine chimerism monitoring is the single most important factor in improving outcomes.

6. Frequently Asked Questions (FAQ)

1. Is rejection the same as Graft-versus-Host Disease?
No. Rejection is the host rejecting the graft (failure to engraft). GvHD is the graft attacking the host (immune-mediated tissue damage).

2. What is the most common cause of rejection?
HLA incompatibility and insufficient conditioning regimens are the most common primary drivers.

3. Can I have a transplant if I have Donor-Specific Antibodies?
Yes, but it is considered a high-risk procedure. Desensitization protocols, such as plasmapheresis or rituximab, are often required.

4. How is chimerism measured?
It is measured using STR-PCR, which distinguishes between the genetic markers of the donor and the recipient.

5. Why is umbilical cord blood more prone to rejection?
Cord blood units contain a limited number of hematopoietic stem cells, which can struggle to establish a niche compared to peripheral blood or bone marrow grafts.

6. Does rejection always happen immediately?
No. Primary graft failure occurs early, but secondary graft failure can occur weeks or even months after the transplant.

7. Can viral infections cause rejection?
Yes. Viruses like Parvovirus B19 or HHV-6 can suppress marrow function and mimic or precipitate graft failure.

8. What is the role of the conditioning regimen?
The conditioning regimen clears the bone marrow niche and suppresses the recipient's immune system to "make room" for the donor cells and prevent rejection.

9. Is a second transplant always successful?
Not always. Success depends on the patient's performance status, the ability to find a suitable donor, and the cause of the initial rejection.

10. What is the main cause of death in patients with rejection?
Infection is the leading cause of mortality, as the patient remains pancytopenic and immunocompromised for an extended period.

7. Clinical Summary and Best Practices

For the clinical team, managing allogeneic stem cell transplant rejection requires a proactive stance:

• Routine Surveillance: Implement weekly peripheral blood chimerism monitoring for the first 100 days post-transplant.
• Infection Control: Maintain aggressive prophylactic strategies for fungal, bacterial, and viral pathogens in patients showing signs of declining cell counts.
• Multidisciplinary Approach: Engage hematopathology, immunology, and infectious disease specialists early.
• Patient Education: Ensure patients understand the signs of cytopenia (e.g., unusual bruising, persistent fever) and the necessity of immediate reporting.

The field of hematopoietic stem cell transplantation continues to evolve. With the advent of better HLA typing and more sophisticated conditioning regimens, the incidence of classic rejection has decreased. However, for those patients who experience it, rapid intervention and institutional expertise remain the cornerstones of successful salvage therapy.

Disclaimer: This guide is intended for educational purposes for clinical professionals and medical students. It does not replace institutional protocols or the judgment of the attending physician in individual patient cases.